Congestive heart failure (CHF) affects millions of patients worldwide, driven by the heart's progressive loss of pumping efficiency and the body's resulting struggle to manage fluid balance. Even with guideline-directed medical therapy, a substantial portion of patients continue to experience debilitating symptoms, frequent hospitalizations, and declining functional capacity. Corveus Medical is developing a minimally invasive, catheter-based approach designed to interrupt the pathological neural signaling that drives disease progression, with the goal of easing symptom burden and extending quality of life for patients with limited treatment options.